Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma.
Yamamoto Y, Tsunedomi R, Fujita Y, Otori T, Ohba M, Kawai Y, Hirata H, Matsumoto H, Haginaka J, Suzuki S, Dahiya R, Hamamoto Y, Matsuyama K, Hazama S, Nagano H, Matsuyama H.
Yamamoto Y, et al. Among authors: otori t.
Oncotarget. 2018 Mar 30;9(24):17160-17170. doi: 10.18632/oncotarget.24715. eCollection 2018 Mar 30.
Oncotarget. 2018.
PMID: 29682213
Free PMC article.